Treace Medical Concepts will announce Q3 2025 financial results on November 6, 2025, followed by a conference call.
Quiver AI Summary
Treace Medical Concepts, Inc. has announced the release of its third-quarter financial results for 2025, scheduled after the market closes on November 6, 2025. Following the release, management will host a conference call at 4:30 pm ET, and interested investors can register to receive participation details. Treace specializes in surgical treatments for bunions and midfoot deformities and has developed the Lapiplasty® 3D Bunion Correction® System to effectively address these issues. The company also offers additional solutions for various types of bunions and midfoot conditions. Treace encourages investors to visit its website for ongoing updates and to learn more about its innovative products.
Potential Positives
- Treace Medical Concepts is positioning itself as a key player in the medical technology field by focusing on innovative surgical solutions for bunions and related midfoot deformities, which are common issues affecting approximately 65 million Americans.
- The company is set to release its third-quarter financial results on November 6, 2025, indicating transparency and commitment to keeping investors informed about its financial performance.
- Treace's pioneering Lapiplasty® 3D Bunion Correction® System addresses the root cause of bunion deformities, suggesting potential for improved patient outcomes and market differentiation.
- The introduction of additional surgical systems and implants, such as the Adductoplasty® and SpeedMTP® products, showcases Treace's commitment to innovation and meeting diverse surgical needs in the foot and ankle market.
Potential Negatives
- While the release shares upcoming financial results, it does not provide any insight into expected performance, which may concern investors seeking transparency.
- The lack of current financial performance data may indicate that the company is not meeting market expectations, potentially leading to decreased investor confidence.
- There is no mention of any significant advancements or improvements in sales or product adoption, potentially signaling stagnation in growth within a competitive market.
FAQ
When will Treace Medical Concepts release its Q3 2025 financial results?
Treace Medical Concepts will release its Q3 2025 financial results on November 6, 2025, after the market closes.
How can I listen to the Treace conference call?
Interested investors can register to receive dial-in numbers and a unique pin to join the conference call.
What is the Lapiplasty® 3D Bunion Correction® System?
The Lapiplasty® 3D Bunion Correction® System is a patented method designed to correct bunion deformities in three dimensions.
Where can I find Treace's investor relations information?
Treace regularly posts important investor information in the “Investor Relations” section of its website at www.treace.com.
What technologies does Treace offer for midfoot deformities?
Treace offers several systems including the Adductoplasty® and SpeedMTP® for midfoot deformity corrections and minimally invasive surgeries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TMCI Hedge Fund Activity
We have seen 61 institutional investors add shares of $TMCI stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,072,324 shares (+241.0%) to their portfolio in Q2 2025, for an estimated $6,305,265
- CIBC PRIVATE WEALTH GROUP LLC removed 606,002 shares (-26.4%) from their portfolio in Q2 2025, for an estimated $3,563,291
- CENTERBOOK PARTNERS LP added 562,710 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,308,734
- MORGAN STANLEY removed 512,714 shares (-33.5%) from their portfolio in Q2 2025, for an estimated $3,014,758
- GAGNON SECURITIES LLC added 503,612 shares (+28.8%) to their portfolio in Q2 2025, for an estimated $2,961,238
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 409,105 shares (+82.0%) to their portfolio in Q2 2025, for an estimated $2,405,537
- DEUTSCHE BANK AG\ removed 358,629 shares (-27.9%) from their portfolio in Q2 2025, for an estimated $2,108,738
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TMCI Price Targets
Multiple analysts have issued price targets for $TMCI recently. We have seen 3 analysts offer price targets for $TMCI in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $7.0 on 10/15/2025
- Rick Wise from Stifel set a target price of $6.0 on 08/08/2025
- Danielle Antalffy from UBS set a target price of $6.5 on 08/08/2025
Full Release
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering . Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/ .
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty ® 3D Bunion Correction ® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace introduced its Adductoplasty ® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP ® Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty ® 3D Minimally Invasive Bunion Correction System and the Percuplasty ™ Percutaneous 3D Bunion Correction System. Treace continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate ® Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty ® , Adductoplasty ® and SpeedMTP ® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com .
To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram .
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
[email protected]
